Table 1.
Frequency and outcomes of Ph-like ALL in children, adolescents and adults.
| Study | Age (years) | Total (Ph-like) | Frequency Ph-like | Outcomes (Ph-like vs. B-other) |
|---|---|---|---|---|
| Jain et al. [20] | 15–39 | 80 (33) | 42% | 5-yr OS (all ages) 23% vs. 59% (p = 0.006) |
| 40–84 | 68 (16) | 24% | ||
| Herold et al. [19] | 16–20 | 26 (5) | 19% | 5-yr DFS (all ages) 19% vs. 57% (p = 0.001) |
| 21–39 | 68 (12) | 18% | 5-yr OS (all ages) 22% vs. 64% (p = 0.006) | |
| 40–55 | 45 (4) | 9% | ||
| 55–84 | 67 (5) | 7% | ||
| Boer et al. [24] | 16–20 | 24 (6) | 25% | 5-yr EFS (all ages) 24% vs. 42% (NR) |
| 21–39 | 48 (9) | 19% | 5-yr OS (all ages) 33% vs. 50% (NR) | |
| 40–71 | 55 (6) | 11% | ||
| Roberts et al. [23] | 21–39 | 344 (96) | 28% | 5-yr EFS 24% vs. 61% (p < 0.0001) |
| 40–59 | 304 (62) | 20% | 5-yr EFS 21% vs. 39% (p = 0.0021) | |
| 60–86 | 150 (36) | 24% | 5-yr EFS 8% vs. 33% (p = 0.47) | |
| Roberts et al. [21] | 1–15 | 853 (108) | 13% | 5-yr EFS 58% vs. 84% (p < 0.001) |
| 16–20 | 372 (77) | 21% | 5-yr EFS 41% vs. 83% (p < 0.001) | |
| 21–39 | 168 (46) | 27% | 5-yr EFS 24% vs. 63% (p < 0.001) | |
| Loh et al. [17] | 1–31 | 572 (81) | 14% | 5-yr EFS 63% vs. 86% (p < 0.0001) |
| Reshmi et al. [18] | 1–31 | 1389 (284) | 20% | NR |
Jain B-other: non-BCR-ABL1. Herold, Boer, Roberts B-other: KMT2A-wild type (WT) and non-BCR-ABL1. Loh B-other: non-BCR-ABL1. Roberts and Loh limited to NCI high risk patients. Reshmi includes patients eligible for Children’s Oncology Group high risk B-ALL study AALL1131. OS = overall survival, 5-yr EFS = event-free survival at 5 years, NR = not reported.